Reduced Fracture Rates Observed Only in Patients With Proper Persistence and Compliance With Bisphosphonate Therapies
- 1 December 2007
- journal article
- review article
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 100 (12) , 1214-1218
- https://doi.org/10.1097/smj.0b013e31815a9685
Abstract
Numerous studies have analyzed data from administrative claims databases to determine persistence and compliance with bisphosphonate therapy for osteoporosis; several of these studies have also examined how persistence and compliance with therapy affect fracture outcomes. All of the studies included in this review demonstrated that patients who were persistent or compliant with therapy had a decreased risk of fracture. None, however, adequately addressed the question of what level of persistence or compliance is necessary to obtain a reduced risk of fracture. There is agreement among studies that compliance and persistence rates are suboptimal for all osteoporosis treatments. Measures to improve persistence and compliance with osteoporosis medications are needed if patients are to achieve the full clinical benefit of treatment.Keywords
This publication has 29 references indexed in Scilit:
- Adherence and persistence: Impact on outcomes and health care resourcesBone, 2006
- Better Osteoporosis Management a PriorityJAMA, 2005
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- ACOG Practice Bulletin #50: OsteoporosisObstetrics & Gynecology, 2004
- American Association of Clinical Endocrinologists Medical Guidelines For Clinical Practice For The Prevention and Treatment of Postmenopausal Osteoporosis: 2001 Edition, With Selected Updates For 2003Endocrine Practice, 2003
- III. Meta-Analysis of Risedronate for the Treatment of Postmenopausal OsteoporosisEndocrine Reviews, 2002
- II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal WomenEndocrine Reviews, 2002
- A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis.Osteoporosis International, 2001
- Prevalence of Osteoporosis in Women Referred for Bone Density TestingJournal of Clinical Densitometry, 1998
- Perspectives: How many women have osteoporosis now?Journal of Bone and Mineral Research, 1995